Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer.

Overexpression of RhoA in cancer indicates a poor prognosis, because of increased tumor cell proliferation and invasion and tumor angiogenesis. We showed previously that anti-RhoA small interfering RNA (siRNA) inhibited aggressive breast cancer more effectively than conventional blockers of Rho-mediated signaling pathways. This study reports the efficacy and lack of toxicity of intravenously administered encapsulated anti-RhoA siRNA in chitosan-coated polyisohexylcyanoacrylate (PIHCA) nanoparticles in xenografted aggressive breast cancers (MDA-MB-231). The siRNA was administered every 3 days at a dose of 150 or 1500 microg/kg body weight in nude mice. This treatment inhibited the growth of tumors by 90% in the 150-microg group and by even more in the 1500-microg group. Necrotic areas were observed in tumors from animals treated with anti-RhoA siRNA at 1500 microg/kg, resulting from angiogenesis inhibition. In addition, this therapy was found to be devoid of toxic effects, as evidenced by similarities between control and treated animals for the following parameters: body weight gain; biochemical markers of hepatic, renal, and pancreatic function; and macroscopic appearance of organs after 30 days of treatment. Because of its efficacy and the absence of toxicity, it is suggested that this strategy of anti-RhoA siRNA holds significant promise for the treatment of aggressive cancers.

An LNA-based loss-of-function assay for micro-RNAs.

MicroRNAs (miRNAs) have recently emerged as being essential for development and for the control of cell proliferation/differentiation in various organisms. However, little is known about miRNA function and mode of action at the cellular level. We have designed a miRNA loss-of-function assay, based on chemically modified locked nucleic acids (LNA) antisense oligonucleotides and usable in tissue culture cells. We show that LNA/DNA mixed oligonucleotides form highly stable duplexes with miRNAs in vitro. Ex vivo, the target miRNA becomes undetectable in cells transfected with the antisense oligonucleotide. The effect is dose-dependent, long-lasting, and specific. Moreover, using a reporter assay, we show that antisense LNA/DNA oligonucleotides inhibit short non-coding RNAs at the functional level. Thus LNA/DNA mixmers represent powerful tools for functional analysis of miRNAs.

The Rb/chromatin connection and epigenetic control: opinion.

The balance between cell differentiation and proliferation is regulated at the transcriptional level. In the cell cycle, the transition from G1 to S phase (G1/S transition) is of paramount importance in this regard. Indeed, it is only before this point that cells can be oriented toward the differentiation pathway: beyond, cells progress into the cycle in an autonomous manner. The G1/S transition is orchestrated by the transcription factor E2F. E2F controls the expression of a group of checkpoint genes whose products are required either for the G1-to-S transition itself or for DNA replication (e.g. DNA polymerase alpha). E2F activity is repressed in growth-arrested cells and in early G1, and is activated at mid-to-late G1. E2F is controlled by the retinoblastoma tumor suppressor protein Rb. Rb represses E2F mainly by recruiting chromatin remodeling factors (histone deacetylases and SWI/SNF complexes), the DNA methyltransferase DNMT1, and a histone methyltransferase. This review will focus on the molecular mechanisms of E2F repression by Rb during the cell cycle and during cell-cycle exit by differentiating cells. A model in which Rb irreversibly represses E2F-regulated genes in differentiated cells by an epigenetic mechanism linked to heterochromatin, and involving histone H3 and promoter DNA methylation, is discussed.

Peptide nucleic acids directed to the promoter of the alpha-chain of the interleukin-2 receptor.

Two 10-mer oligopyrimidine peptide nucleic acids (PNAs) were designed to interfere with IL-2R alpha promoter expression by binding to the regulatory sequences overlapping SRF and NF-kappa B transcription factor sites. Specific complexes were formed on each target sequence, and clearly involved (1) Hoogsteen hydrogen bonds as shown by experiments in which the purine strand of a single or double-stranded target was substituted with 7-deazadeoxyguanosine, (2) P-loop formation on double-helical DNA as evidenced by susceptibility to a single-strand-specific nuclease. When formed on a single-stranded DNA target, these highly stable complexes were responsible for efficient physical blockage of T7 DNA polymerase elongation on the template DNA containing the target oligopurine sequence. On a double-stranded target, these complexes only formed at low ionic strength and were slowly dissociated at physiological ionic strength (pH 6.5) with a t1/2 of 6.5-7 h. The salt-dependent instability of preformed complexes on a plasmid target was probably the critical factor responsible for their lack of significant sequence-specific effect on IL-2R alpha promoter activity inside living cells.

Dose-dependence of the augmentation of hemopoiesis by thymocytes.

We have used the spleen colony assay and the 24-h uptake of 59Fe by hemopoietic tissues to study certain quantitative aspects of the interaction of parent-strain thymocytes and marrow cells transplanted into lethally irradiated F1 hybrid mice. The data show that thymocytes augment bone marrow growth at least partly by increasing the proportion of stem cells from parental marrow that from colonies in the hybrid animal. This increase in spleen colony number is a linear function of the number of thymocytes injected within certain dose ranges. At higher thymocytes doses, a plateau is reached where further increase in the number of thymocytes injected does not result in an increase in the number of spleen colonies; this plateau occurs at just that level of response given by the same marrow dose when transplanted into isogeneic (parent-strain) recipients. Experiments in which 59Fe uptake up red blood cells and spleen was used to measure marrow growth yielded similar results, except that the plateau in uptake occurred at a much lower level than that measured for the same marrow dose in isogeneic recipients. This apparent discrepancy in results obtained from the two different assays may best be explained by the recent observation that thymocytes shift the differentiation pattern of marrow stem cells away from erythropoiesis and toward granulopoiesis. The absolute thymocyte dose seems to be more important than the thymocyte: marrow-cell ratio in determining the degree of augmentation observed.

Augmentation of marrow growth by thymocytes separated by discontinuous albumin density-gradient centrifugation.

Mouse thymocytes were separated by discontinuous albumin density-gradient centrifugation. The ability of B6 thymocytes from the gradient fractions to increase the number of spleen nodules formed by B6 marrow cells in B6D2F1 recipients was compared with that of similar numbers of B6 thymocytes from an unfractionated cell suspension. Thymocytes from any of the gradient fractions were not more effective than thymocytes from an unfractionated suspension in augmenting marrow-cell growth, indicating that the presumptive 'effective cell type' in this system cannot be separated from the total thymocyte population by its buoyant density properties.

Interactions of major and minor histocompatibility antigens in the graft-versus-host reaction.

The greater severity of the graft-versus-host (GVH) reaction induced by grafting C57BL/6(B6) lymphoid or bone marrow cells to irradiated (B6 x DBA/2)F1 recipients, as compared to that induced in H-2-identical (B6 x BALB/c)F1 recipients, has been shown to arise from a synergistic effect of H-2d and DBA/2 minor histocompatibility antigens (MiHAs), and not from a difference in the intensity of genetic resistance to B6 cell grafts exhibited by the two F1s. Furthermore, detection of such synergistic effects depends upon choice of an appropriate assay system; GVH splenomegaly results cannot be used to predict the outcome of a systemic GVH reaction.

Alloimmunization-activated suppressor cells. II. In vitro activity of suppressor cells implicated in the abrogation of lethal graft-versus-host reaction.

Incompatibility for DBA/2 (D2) minor histocompatibility antigens (MiHA) alone leads to a severe lethal graft-versus-host reaction (GVHR) in irradiated (D2 X B10.D2)F1 mice receiving a bone-marrow-plus-spleen-cell graft from B10.D2 donors. This mortality is abrogated when the donors are preimmunized simultaneously against specific D2 MiHA and unrelated H-2 antigens three days before grafting. Results presented here demonstrate that spleen cells from such preimmunized donors, which are able to diminish the intensity of the GVHR developed by normal cells, exhibit the following properties: (1) reduced proliferative response to D2 MiHA in one-way MLC; (2) radioresistant suppressive effect on the proliferative responses of both normal and specifically primed B10.D2 cells; (3) inability to lyse D2 target cells even after in vitro boosting, implying that the suppressive effect detected in vitro is not due to removal of the stimulating antigens from the culture; and (4) inability to suppress the development of an anti-MiHA cytolytic response by specifically primed B10.D2 cells, despite a pronounced suppressive effect on their proliferation. Taken together with the GVHR observations, these results suggest that simultaneous immunization against specific MiHA and unrelated H-2 antigens activates, in the spleens of treated donors, suppressor cells that can inhibit the immune response at the recognition phase, and probably also at an afferent, but not efferent, stage of cytotoxic effector-cell differentiation.

Alloimmunization-activated suppressor cells. I: Abrogation of lethal graft-versus-host reaction directed against non-H-2 antigens.

Incompatibility for DBA/2 (D2) minor histocompatibility antigens (MiHA) alone leads to a severe lethal graft-versus-host reaction (GVHR) in adult (D2 X B10.D2)F1 recipients of B10.D2 bone marrow and spleen cells. In this genetic combination, mortality is completely abrogated by preimmunization of the graft donor against unrelated H-2b antigens and specific D2 MiHA a short time before grafting. Protection against GVHR mortality is elicited by immunizing the donors with a single transfusion of incompatible spleen cells or whole blood. Abrogation of GVHR mortality is due mainly to the immunization with specific MiHA, and only to a much lesser degree to the immunization with unrelated H-2 antigens; the protective effect induced by association of these two types of immunization, however, is significantly better than that elicited by either type of immunization alone. It is unlikely that this abrogation of GVHR mortality results from "dilution" of specifically reactive cells; rather, suppressor cells appear to be a contributing factor, because the preimmunization activates, in the donor spleen, suppressor cells capable of decreasing the severity of the GVHR developed against MiHA by normal cells. Histopathologic observations indicated that the lesions induced in various tissues after grafting of preimmunized donor cells were considerably less severe than those induced by grafting of normal donor cells. However, simultaneous immunization with specific MiHA and unrelated H-2 antigens may also exacerbate the GVHR, depending upon the conditions used for preimmunization; abrogation of GVHR mortality is favored by a single immunization with unrelated H-2b antigens and specific MiHA administered simultaneously a short time before grafting, whereas an acceleration of GVHR mortality is favored by long intervals and multiple immunizations. It is suggested that, depending upon the conditions used for the preimmunization, the allogeneic effect produced by stimulation with unrelated H-2 antigens may augment the response to MiHA or it may enhance the activation of suppressor cells that contribute to the abrogation of GVHR mortality.

Lethal graft-versus-host reaction against non-H-2 antigens. I. Prevention of GVH-associated immunodeficiency by preimmunizing the donor against host-specific non-H-2 antigens.

Injection of B10.D2 cells into irradiated H-2d compatible (DBA/2xB10.D2)F1 recipients provokes a lethal GVH that can be abrogated by donor preimmunization against host-specific DBA/2 non-H-2 antigens. To study the possible relationship between the observed protection and restoration of immune responsiveness, we compared spleen cellularity, selected T and B cell functions, and NK activity in GVH and protected mice during the 1st month after grafting. Normal and isografted mice served as controls. GVH was found to be characterized by an early stimulation phase associated with splenomegaly and increased percentages (but not numbers) of Lyt-2+ and L3T4+ cells, followed by profound aplasia and abrogation of IL-2 production. Response to a B cell mitogen (LPS) is depressed, and cells from GVH mice exert a strong suppressive effect on the LPS and PHA responsiveness of normal cells. Suppression appears to be mediated by a radioresistant, nylon nonadherent, asialo GM1 negative cell expressing a low level of Thy-1 antigen. In contrast, protection correlates with progressive restoration of spleen cellularity and LPS responsiveness, with decreased but clearly detectable IL-2 production, and transient nonspecific suppressor activity. The immune status of protected mice resembles that of isografted controls. No correlation was found between mortality (or protection) and either PHA responsiveness, which remained depressed in all grafted mice throughout the observation period, or NK activity, which was strongly depressed in both GVH and protected mice. In conclusion, protection correlates with the disappearance of nonspecific suppressor cells and the restoration of cellularity and certain nonspecific immune functions. Donor immunization against host-specific non-H-2 antigens, which protects against mortality, also protects against GVH-associated immune deficiency.

Autonomously binding protein detected on ets box of c-fos serum response element in proliferating cells.

The serum response element (SRE) in the c-fos promoter contains an ets box whose integrity is required for full activation of this proto-oncogene by nerve growth factor (NGF) in PC12 rat pheochromocytoma cells. Electrophoretic mobility shift assays (EMSA) detect a protein in nuclear extracts that binds to the wild-type SRE, but not to an SRE containing a mutated ets box. Competition studies using unlabeled probes, and supershift experiments using antibodies and in vitro translated core serum response factor (SRF) indicate that the protein in question is not YY1, SAP-1, nor Elk-1 and that it does not exhibit ternary complex factor (TCF) activity, so that it may correspond to an autonomously binding Ets family protein. The complete disappearance of this "Ets-like autonomous binding factor" upon terminal differentiation of both L6alpha2 myoblastic and PC12 pheochromocytoma cells points to a possible role in the proliferation/differentiation process.

Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.

Overexpression of RhoA or RhoC in breast cancer indicates a poor prognosis, due to increased tumor cell proliferation and invasion and tumor-dependent angiogenesis. Until now, the strategy of blockage of the Rho-signaling pathway has used either GGTI or HMG-CoA reductase inhibitors, but they are not specific to RhoA or RhoC inhibition. In this study, a new approach with anti-RhoA and anti-RhoC siRNAs was used to inhibit specifically RhoA or RhoC synthesis. Two transfections of either RhoA or RhoC siRNA (8.5 nM) into MDA-MB-231 human breast cancer cells or HMEC-1 endothelial cells induced extensive degradation of the target mRNA and led to a dramatic decrease in synthesis of the corresponding protein. In vitro, these siRNAs inhibited cell proliferation and invasion more effectively than conventional blockers of Rho cell signaling. Finally, in a nude mouse model, intratumoral injections of anti-RhoA siRNA (100 microl at 85 nM) every 3 days for 20 days almost totally inhibited the growth and angiogenesis of xenografted MDA-MB-231 tumors. One may infer from these observations that specific inhibition of the Rho-signaling pathway with siRNAs represents a promising approach for the treatment of aggressive breast cancers.

Abrogation of the lethal graft-vs.-host reaction developed to non-H-2 antigens: involvement of T suppressor cells distinct from veto cells.

The mortality induced by graft-vs.-host reaction (GVHR) in (DBA/2 x B10.D2)F1 recipients transplanted with cells from H-2d-identical B10.D2 donors can be abrogated by preimmunizing the donors with parent-strain spleen cells from normal DBA/2 mice. The experiments described here were designed to explore the possibility that the observed protection might be mediated by veto cells contained in the immunizing cell inoculum; the reasoning was based on an analogy with the cytotoxic T lymphocyte response to non-H-2 antigens where suppression can be mediated by veto cells, present in the spleens of normal mice, which are radiosensitive and largely Lyt-2+. We show that the intensity of the protection against GVHR mortality is a function of the immunizing cell dose, and that protection remains effective when optimal doses of immunizing cells are (a) irradiated or (b) pretreated with anti-Thy-1 serum. GVHR suppression is abrogated when, before transfer to F1 recipients, suppressor cells from spleens of immunized donors are pretreated with antiserum directed against Lyt-1.2 (expressed by B10.D2 but not by DBA/2, which expresses Lyt-1.1); in contrast, it is not significantly affected when these same cells are pretreated with anti-Lyt-2.2 alloantiserum. We conclude that when the antigen load is great enough the immunizing cells play a largely passive role in the observed suppression. The protection against GVHR mortality seen in this H-2-compatible combination is transferable by Lyt-1+2- suppressor T cells originating in mice given high doses of alloantigen. These suppressor cells are therefore distinct from the splenic veto T cells effective against cytotoxic T lymphocyte responses to non-H-2 antigens. The mechanism of the observed suppression and its relationship to Mls product(s) are discussed.

Parameters involved in the induction and abrogation of the lethal graft-versus-host reaction directed against non-H-2 antigens.

The grafting of cells from donors incompatible for non-H-2 antigens alone can lead to GvHR mortality in up to 100% of lethally irradiated adult recipients. GvHR severity correlates with the number of mature immunocompetent cells present in the bone marrow inoculum. Histologic and clinical manifestations of GvHR observed in these mice differ from those seen when GvHR is induced across an H-2 barrier. The number of non-H-2 genes capable of influencing GvHR mortality is probably great, and their effects may vary as a function of sex. The non-H-2 genes influence GvHR mortality mainly via their interactions, the consequences of which are complex and can result in either cumulative or suppressive effects. GvHR mortality is considerably reduced by donor immunization, shortly before grafting, against host-specific non-H-2 antigens; and it is virtually abrogated by an additional immunization of the donors against nonspecific (foreign) H-2 antigens. Three weeks after grafting, these "protected" mice are easily distinguishable from those undergoing lethal GvHR, as assessed by both clinical appearance and histologic examination; in contrast, they are nearly indistinguishable from control mice grafted with syngeneic cells. However, depending upon the conditions used for the immunization, an additional immunization against nonspecific H-2 antigens can lead to acceleration rather than suppression of GvHR mortality; this phenomenon is not seen, under the same experimental conditions, after immunization against specific non-H-2 antigens alone. It is therefore suggested that a "second signal" provided by an additional nonspecific stimulus can potentiate either the establishment of specific suppression or the activation of a secondary ("positive") response. Suppressive effects of the specific and nonspecific immunizations are cumulative, and both treatments activate suppressor cells. The intensity of suppression induced by both specific and nonspecific immunizations is antigen dose-dependent. At equivalent antigen doses the specific immunization is considerably more effective than the nonspecific immunization, and is detectable after injection of as few as 2.5 X 10(5) cells. In both cases, irradiation of the immunizing cells abolishes the suppression induced by the lower cell doses tested, while it merely decreases the intensity of the suppression induced by the higher cell doses tested. The impairment of suppression after irradiation of the immunizing cells is not attributable to a modification of their homing pattern, but to the fact that proliferation of the immunizing cells, which leads to an augmentation of the antigen dose, is abolished by irradiation.(ABSTRACT TRUNCATED AT 400 WORDS)

Abrogation of lethal graft-versus-host reaction directed against non-H-2 antigens: role of Mlsa and K/I region antigens in the induction of unresponsiveness by alloimmunization.

A graft-versus-host reaction (GVHR) directed against DBA/2 non-H-2 antigens alone can be induced by grafting B10.D2 bone marrow and spleen cells intravenously to heavily irradiated, H-2d compatible (DBA/2 X B10.D2)F1 adult mice. Under the experimental conditions used, only 0-10% of recipients survive, but the survival is greatly increased by donor alloimmunization, a few days prior to grafting, against host-specific (DBA/2) non-H-2 antigens and non-specific (foreign) H-2 antigens. The increased survival is mediated by alloimmunization-activated suppressor cells which can decrease the intensity of the immune reaction developed by normal B10.D2 cells both in vivo (GVHR) and in vitro (proliferative response measured in mixed lymphocyte culture, MLC). The present experiments were designed to explore the antigenic requirements for inducing suppression. The results showed that in GVHR the protective effect induced by donor alloimmunization against the specific non-H-2 antigens, which leads to 70-80% survival, is due primarily, if not entirely, to immunization against Mlsa antigens. Results of MLC experiments confirmed this conclusion, showing that immunization against Mlsa antigens is sufficient to account for the suppressive effect induced by the specific immunization. In addition, they indicated that the non-specific protective effect induced by donor alloimmunization against foreign H-2 antigens, which leads to 20-30% survival, is due to immunization against antigens encoded by the K and/or I region(s) of the H-2 complex; immunization against D region encoded antigens alone has no effect.

Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction.

In the immunosuppression accompanying the lethal systemic graft-versus-host reaction (GVHR) directed against minor histocompatibility antigens in irradiated adult mice, we previously determined that non-T, non-B, L-leucine methyl ester (LME)-sensitive cells were implicated via two different mechanisms: one, which is interferon-gamma (IFN-gamma)-dependent and affects both T-cell proliferative responses and thymus-independent antibody production by CD5(+) B cells; and a second, which is IFN-gamma-independent and affects B-cell proliferative responses. Because IFN-gamma induces the production of nitric oxide (NO), a potent immunosuppressive molecule, we investigated the involvement of NO in the suppression mediated by the LME-sensitive cells. Inducible NO synthase (iNOS) mRNA, iNOS protein, and the stable end products of iNOS pathway, L-citrulline and nitrite, were detected early in GVHR in LME-sensitive spleen cells taken ex vivo and could be amplified in vitro by T and B mitogens. Inhibition of NO production with arginine analogs (aminoguanidine, N(G)-monomethyl-L-arginine [LMMA]), like anti-IFN-gamma antibodies, reversed suppression of both T-cell responses to concanavalin A and CD5(+) B-cell responses, but not of B-cell response to lipopolysaccharides (LPS). The GVHR-associated, IFN-gamma-dependent immunosuppression of T-cell proliferation and of antibody synthesis by CD5(+) B cells is the consequence of NO production by LME-sensitive cells. Immunohistochemical analyses indicate that these cells belong to the macrophage lineage.